A Phase III study published in NEJM shows the dapivirine ring safely reduced HIV infection by 31 percent overall among all women in the trial. The risk of HIV infection was reduced by at least 56 percent among women who used the ring consistently, with subgroup analyses suggesting a 75 percent or more reduction with near-perfect use.
The monthly dapivirine vaginal ring provides significant protection against HIV infection in women, with consistent use reducing risk by at least 56%. Two open-label studies have launched to further investigate the product's efficacy and support its consistent use.
Two large studies confirm the monthly vaginal ring's effectiveness in preventing HIV-1 infection in women, with a 30% overall reduction in infections. The ring's efficacy varies by age and consistent use, highlighting the need to overcome barriers to prevention for younger women.
Two new HIV prevention products, a combination antiretroviral vaginal ring and a film releasing the drug dapivirine, show safety and hold promise for further development. The products aim to provide an array of options for women-initiated prevention tools against HIV.